Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 3;16(11):e72952.
doi: 10.7759/cureus.72952. eCollection 2024 Nov.

Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis

Affiliations
Case Reports

Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis

Shamira Sibal et al. Cureus. .

Abstract

Nilotinib, a tyrosine kinase inhibitor (TKI) used in patients of chronic myeloid leukemia (CML), has been known to cause atherosclerosis and arterial stenosis as a rare complication of long-term or high-dose therapy. Patients in this group are more likely to have coronary or peripheral artery disease; intracranial involvement is comparatively uncommon. Furthermore, studies on nilotinib-induced ischemia in Indian populations are scarce. Here, we present a case of ischemic stroke in a patient on long-term nilotinib treatment who, prior to treatment, had no risk factors for stroke. He presented with subacute symptoms of ataxia, motor and sensory deficit, and a raised low-density lipoprotein. MRI revealed multifocal arterial stenosis, as well as areas of infarction and hypoperfusion in the left cerebral hemisphere. Nilotinib therapy was immediately stopped; the patient was treated with dual antiplatelets, statins, and physiotherapy, and he had no major focal deficits on discharge. However, this case serves as a good reminder that even for patients considered to be largely safe from cardiovascular adverse events, regular monitoring of cardiovascular parameters is important so that timely preventive action can be initiated if necessary.

Keywords: chronic myeloid leukemia (cml); drug-induced stroke; long term chemotherapy; multifocal intracranial atherosclerosis; nilotinib; vascular adverse effects; young stroke.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. MRI showing areas of brain infarcts
Acute left posterior cerebral artery territory infarcts are seen involving the left occipital lobe, left temporal region along para-hippocampal gyrus, left crus of midbrain, and left red nucleus. This is seen in (A) diffusion-weighted imaging, (B) apparent diffusion coefficient,  and (C) fluid-attenuated inversion recovery images.
Figure 2
Figure 2. MRA of intracranial arteries
(A) Focal high-grade stenosis is seen in the left supraclinoid ICA (blue arrow) causing 70-80% narrowing. The right supraclinoid ICA also showing moderate 40-50% narrowing (orange arrow) and focal moderate narrowing in the proximal M1 segment of right MCA (yellow arrow). (B) Focal occlusion of the P1 segment of left PCA (pink arrow). MRA: magnetic resonance angiography; PCA: posterior cerebral artery; ICA: internal carotid artery; MCA: middle cerebral artery

References

    1. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Am J Hematol. 2011;86:533–539. - PubMed
    1. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Leukemia. 2017;31:2388–2397. - PMC - PubMed
    1. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Hochhaus A, Saglio G, Hughes TP, et al. Leukemia. 2016;30:1044–1054. - PMC - PubMed
    1. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Kantarjian HM, Hughes TP, Larson RA, et al. Leukemia. 2021;35:440–453. - PMC - PubMed
    1. Clinical cardiac safety profile of nilotinib. Kim TD, le Coutre P, Schwarz M, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366654/ Haematologica. 2012;97:883–889. - PMC - PubMed

Publication types

LinkOut - more resources